Rohit Loomba1, Zeid Kayali2, Mazen Noureddin3, Peter Ruane4, Eric J Lawitz5, Michael Bennett6, Lulu Wang7, Eliza Harting7, Jacqueline M Tarrant7, Bryan J McColgan7, Chuhan Chung7, Adrian S Ray7, G Mani Subramanian7, Robert P Myers7, Michael S Middleton8, Michelle Lai9, Michael Charlton10, Stephen A Harrison11. 1. University of California at San Diego, La Jolla, California. Electronic address: roloomba@ucsd.edu. 2. Inland Empire Liver Foundation, Rialto, California. 3. Cedars-Sinai Medical Center, Los Angeles, California. 4. Ruane Medical and Liver Health Institute, Los Angeles, California. 5. Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas. 6. Medical Research Associates Group, San Diego, California. 7. Gilead Sciences, Inc, Foster City, California. 8. University of California at San Diego, La Jolla, California. 9. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 10. University of Chicago, Chicago, Illinois. 11. Pinnacle Clinical Research, San Antonio, Texas.
Abstract
BACKGROUND & AIMS: De novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step in this process. We evaluated the safety and efficacy of GS-0976, an inhibitor of acetyl-coenzyme A carboxylase in liver, in a phase 2 randomized placebo-controlled trial of patients with NASH. METHODS: We analyzed data from 126 patients with hepatic steatosis of at least 8%, based on the magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), and liver stiffness of at least 2.5 kPa, based on magnetic resonance elastography measurement or historical biopsy result consistent with NASH and F1-F3 fibrosis. Patients were randomly assigned (2:2:1) to groups given GS-0976 20 mg, GS-0976 5 mg, or placebo daily for 12 weeks, from August 8, 2016 through July 18, 2017. Measures of hepatic steatosis, stiffness, serum markers of fibrosis, and plasma metabolomics were evaluated. The primary aims were to confirm previous findings and evaluate the relation between dose and efficacy. RESULTS: A relative decrease of at least 30% from baseline in MRI-PDFF (PDFF response) occurred in 48% of patients given GS-0976 20 mg (P = .004 vs placebo), 23% given GS-0976 5 mg (P = .43 vs placebo), and 15% given placebo. Median relative decreases in MRI-PDFF were greater in patients given GS-0976 20 mg (decrease of 29%) than those given placebo (decrease of 8%; P = .002). Changes in magnetic resonance elastography-measured stiffness did not differ among groups, but a dose-dependent decrease in the fibrosis marker tissue inhibitor of metalloproteinase 1 was observed in patients given GS-0976 20 mg. Plasma levels of acylcarnitine species also decreased in patients with a PDFF response givenGS-0976 20 mg. GS-0976 was safe, but median relative increases of 11% and 13% in serum levels of triglycerides were observed in patients given GS-0976. CONCLUSIONS: In a randomized placebo-controlled trial of patients with NASH, we found 12-week administration of GS-0976 20 mg decreased hepatic steatosis, selected markers of fibrosis, and liver biochemistry. ClinicalTrials.gov ID NCT02856555.
RCT Entities:
BACKGROUND & AIMS: De novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step in this process. We evaluated the safety and efficacy of GS-0976, an inhibitor of acetyl-coenzyme A carboxylase in liver, in a phase 2 randomized placebo-controlled trial of patients with NASH. METHODS: We analyzed data from 126 patients with hepatic steatosis of at least 8%, based on the magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), and liver stiffness of at least 2.5 kPa, based on magnetic resonance elastography measurement or historical biopsy result consistent with NASH and F1-F3 fibrosis. Patients were randomly assigned (2:2:1) to groups given GS-0976 20 mg, GS-0976 5 mg, or placebo daily for 12 weeks, from August 8, 2016 through July 18, 2017. Measures of hepatic steatosis, stiffness, serum markers of fibrosis, and plasma metabolomics were evaluated. The primary aims were to confirm previous findings and evaluate the relation between dose and efficacy. RESULTS: A relative decrease of at least 30% from baseline in MRI-PDFF (PDFF response) occurred in 48% of patients given GS-0976 20 mg (P = .004 vs placebo), 23% given GS-0976 5 mg (P = .43 vs placebo), and 15% given placebo. Median relative decreases in MRI-PDFF were greater in patients given GS-0976 20 mg (decrease of 29%) than those given placebo (decrease of 8%; P = .002). Changes in magnetic resonance elastography-measured stiffness did not differ among groups, but a dose-dependent decrease in the fibrosis marker tissue inhibitor of metalloproteinase 1 was observed in patients given GS-0976 20 mg. Plasma levels of acylcarnitine species also decreased in patients with a PDFF response given GS-0976 20 mg. GS-0976 was safe, but median relative increases of 11% and 13% in serum levels of triglycerides were observed in patients given GS-0976. CONCLUSIONS: In a randomized placebo-controlled trial of patients with NASH, we found 12-week administration of GS-0976 20 mg decreased hepatic steatosis, selected markers of fibrosis, and liver biochemistry. ClinicalTrials.gov ID NCT02856555.
Authors: David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman Journal: J Physiol Date: 2019-01-02 Impact factor: 5.182
Authors: Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer Journal: JCI Insight Date: 2020-03-12
Authors: Veeral H Ajmera; Edward Cachay; Christian Ramers; Irine Vodkin; Shirin Bassirian; Seema Singh; Neeraj Mangla; Richele Bettencourt; Jeannette L Aldous; Daniel Park; Daniel Lee; Jennifer Blanchard; Adrija Mamidipalli; Andrew Boehringer; Saima Aslam; Olof Dahlqvist Leinhard; Lisa Richards; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2019-06-18 Impact factor: 17.425
Authors: Jonathan G Stine; Nagambika Munaganuru; Abbey Barnard; Jennifer L Wang; Kellee Kaulback; Curtis K Argo; Siddarth Singh; Kathryn J Fowler; Claude B Sirlin; Rohit Loomba Journal: Clin Gastroenterol Hepatol Date: 2020-08-31 Impact factor: 11.382